Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines-Reference-Cited by-同舟云学术

Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines

Published:2016-03-22 Issue:3 Volume:139 Page:510-517
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Brotherton Julia M.L.¹²,Jit Mark³⁴,Gravitt Patti E.⁵,Brisson Marc⁶,Kreimer Aimée R.⁷,Pai Sara I.⁸,Fakhry Carole⁹,Monsonego Joseph¹⁰,Franceschi Silvia¹¹

Affiliation:

1. National HPV Vaccination Program Register, VCS Registries; East Melbourne Vic Australia

2. School of Population and Global Health; University of Melbourne; Vic Australia

3. Modelling and Economics Unit; Public Health England; London United Kingdom

4. Department of Infectious Disease Epidemiology; London School of Hygiene and Tropical Medicine; London United Kingdom

5. Department of Pathology; University of New Mexico Health Sciences Center; Albuquerque NM

6. Département de Médecine Sociale et Préventive; Université Laval; Québec QC Canada

7. Infections & Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH; Bethesda MD

8. Department of Surgery; Harvard Medical School, Massachusetts General Hospital; Boston MA

9. Department of Otolaryngology Head and Neck Surgery; Johns Hopkins School of Medicine, Johns Hopkins Outpatient Center; Baltimore MD

10. Institut du Col; 174 Rue de Courcelles Paris 75017 France

11. International Agency for Research on Cancer; 69372 Lyon cedex 08 France

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference114 articles.

1. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up;Roteli-Martins;Hum Vaccin Immunother,2012

2. Long-term study of a quadrivalent human papillomavirus vaccine;Ferris;Pediatrics,2014

3. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial;Schwarz;Pediatr Infect Dis J,2014

4. A review of clinical trials of human papillomavirus prophylactic vaccines;Schiller;Vaccine,2012

5. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial;Wheeler;Lancet Oncol,2012

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?;Oral Oncology;2021-04

2. Dominican Provider Attitudes Towards HPV Testing for Cervical Cancer Screening and, Current Challenges to Cervical Cancer Prevention in the Dominican Republic: a Mixed Methods Study;Journal of Cancer Education;2020-04-19

3. Internal construct validity of the Brazilian version of a tool for assessing the population’s knowledge of human papillomavirus;Revista Brasileira de Epidemiologia;2020

4. Socio-demographic correlates of cervical cancer risk factor knowledge among screening non-participants in Great Britain;Preventive Medicine;2019-08

5. Barriers to Cervical Cancer Screening and Treatment in the Dominican Republic: Perspectives of Focus Group Participants in the Santo Domingo Area;Journal of Transcultural Nursing;2019-05-03